Conference: 2nd TCE for Autoimmune Disease Summit
日期： 2026 年 10 月 27 - 29 日
地点： The Colonnade Hotel, Boston, MA
Joshua Apgar, PhD
VP, Head of QSP SoftwareDr. Apgar is the VP, Head of QSP Software at Certara, and co-founder of Applied BioMath (acquired by Certara in Dec 2023). Prior to this, Josh was a Principal Scientist in the Systems Biology Group of the Department of Immunology and Inflammation at Boehringer Ingelheim Pharmaceuticals. 他的工作是利用基于物理学的模型：转化体外和体内数据、评估靶点可行性、了解药物作用机制并预测人体剂量。这项工作的最终目标是通过对药物药理学和疾病病理生理学的深入定量研究，减少药物开发后期的损耗。
Joshua 在麻省理工学院获得生物工程博士学位，在那里他从事系统生物学的实验设计工作，研究重点是识别可以用于估算未知参数并揭示信号转导网络复杂机制的可操作性实验。在此之前，Joshua 在 Avaki开发了一个可扩展性极强的软件平台，以支持生命科学和工程领域的高性能计算和企业信息集成。
Global Portfolio Lead, Modeling & Simulation
Scientific Poster
Bridging Oncology and Autoimmune Disease: Using QSP to Select T-Cell Engager Doses by CRS Risk and Efficacy
This research demonstrates how quantitative systems pharmacology (QSP) modeling can leverage existing oncology data to inform T-cell engager (TCE) dose selection for autoimmune diseases, where minimizing cytokine release syndrome (CRS) risk is particularly important. Using a modular QSP model calibrated and validated against published clinical data, researchers simulated 3,030 virtual patients to evaluate efficacy and CRS risk across doses. The findings demonstrate the potential to identify doses that balance therapeutic benefit with safety, while providing a flexible modeling framework that can be adapted to different targets and dosing strategies.
From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.
